A Study to Give Treatment Inside the Eye to Treat Retinoblastoma
Status:
Not yet recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
This phase II trial tests the safety and side effects of adding melphalan to standard
chemotherapy in treating patients with retinoblastoma (RB). RB is a type of cancer that
occurs in the eye. RB is considered harder to treat (higher risk) when there are vitreous
seeds present. Vitreous seeds are RB tumors in the jelly-like fluid of the eye (called the
vitreous). The term, risk, refers to the chance of the cancer not responding to treatment or
coming back after treatment. Chemotherapy drugs, such as melphalan, carboplatin, vincristine,
and etoposide work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Melphalan is more
commonly given later in therapy or in relapsed disease (cancer that has returned after
treatment). Adding melphalan to standard chemotherapy early in treatment may improve the
ability to treat vitreous seeds.